Serum Lipid Goal Attainment in Chronic Kidney Disease (CKD) Patients under the Japan Atherosclerosis Society (JAS) 2012 Guidelines

J Atheroscler Thromb. 2015;22(9):949-57. doi: 10.5551/jat.29165. Epub 2015 Apr 4.

Abstract

Aim: According to the Japan Atherosclerosis Society 2012 guidelines (JAS2012-GL), chronic kidney disease (CKD) has newly been added to the high-risk group in terms of atherosclerotic cardiovascular diseases. We therefore explored the lipid target level achievement rates under the JAS2012-GL in real-world clinical practice.

Methods: We retrospectively reviewed the medical charts of patients who were hospitalized at the Nephrology Department at Kobe City Medical Center General Hospital in the period from April 1, 2012 to May 31, 2013 and explored the serum lipid target level achievement rates. Patients without lipid data or those undergoing regular dialysis because of chronic renal failure were excluded. In this study, the CKD group (CKD-G) did not include CKD patients under secondary prevention for coronary heart disease (CHD) or diabetes mellitus (DM).

Results: The CKD-G included 146 (81.1%) of the 180 enrolled patients. According to the JAS2012-GL, 100% of the CKD-G patients were categorized into the high-risk group, although only 12.1% of the CKD-G subjects were at high risk according to the JAS2007-GL. Under the JAS2012-GL, the LDL cholesterol (LDL-C) and non-HDL cholesterol (non-HDL-C) target level achievement rates for CKD-G were 71.4% and 68.1%, respectively. According to the JAS2007-GL, these rates were 81.3% and 79.1%, respectively, and, under both guidelines, these rates were 71.7% and 72.1% for primary prevention DM and 66.7% and 66.7% for CHD, respectively.

Conclusions: After the revision of the JAS-GL in 2012, the LDL-C and non-HDL-C target level achievement rates for CKD-G were reduced by approximately 10%; however, they remained similar to those for DM and higher than those for CHD.

MeSH terms

  • Aged
  • Atherosclerosis / prevention & control
  • Cardiology / organization & administration
  • Cholesterol / blood*
  • Cholesterol, LDL / blood*
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy
  • Female
  • Guideline Adherence
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Japan
  • Kidney Failure, Chronic / diagnosis
  • Lipoproteins / chemistry
  • Male
  • Middle Aged
  • Practice Guidelines as Topic
  • Renal Insufficiency, Chronic / blood*
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / drug therapy*
  • Retrospective Studies
  • Risk Factors
  • Secondary Prevention
  • Societies, Medical

Substances

  • Cholesterol, LDL
  • Hypolipidemic Agents
  • Lipoproteins
  • Cholesterol